About
Join us for an in-depth webinar exploring how CETSA® Selectivity Profiling empowers smarter decision-making in drug discovery.

Drew Nager will share how Pfizer Oncology leverages Pelago Bioscience’s CETSA Selectivity service to accelerate project progression, while Laurence Arnold from Pelago Bioscience will present case studies demonstrating the impact of the service across diverse targets, modalities, and stages of discovery.

The service offers an unbiased, proteome-wide view of compound interactions accessing biologically relevant targets that conventional selectivity panels often miss.

Powered by automated sample preparation and high-throughput LC/MS proteomics, the service enables analysis of approximately 100 samples/day with quantification of >5,000 proteins in lysate. As a result, you obtain actionable insights within 10 working days, accelerating the DMTA cycle and supporting data-driven lead optimization

Live Q&A: Bring your questions and explore how CETSA Selectivity can be seamlessly integrated into your discovery programs.

All intellectual property rights, including copyrights and trademarks, relating to CETSA are owned by Pelago Bioscience AB.
Presenters
1765994896-6551886ecec20b5a
Drew Nager, PhD
Director of Systems Biology, Pfizer Oncology
Dr. Nager is part of Pfizer’s Oncology Research Unit and works on the discovery of the next generation of small-molecule, biologic, and antibody drug conjugate therapeutics. His research team leverages proteomic and transcriptomic approaches to better understand targets and candidate drugs.
1765994909-b02764cc92a32655
Laurence Arnold, PhD
Head of R&D, Pelago Bioscience
Laurence Arnold is the Head of R&D at Pelago Bioscience. With a background in Protein biochemistry and Biophysics he and his team leverage CETSA data to determine actionable insights from cellular drug:protein interactions alongside developing the next generation of products stemming from target engagement.
1765994919-74fe9e84ea04f2bb
Tove Boström, PhD
Product Manager, Pelago Bioscience
Tove Boström is a Product Manager at Pelago Bioscience, contributing to the development of CETSA-based solutions for drug discovery. With a strong background in proteomics and mass spectrometry, she supports the growing proteomics offering and helps turn customer needs into practical, effective applications.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Country / Region*
Job Title*
Organization / Company*
Organization Type*
Your Therapeutic Area(s)*
utm_bmcr_source
Registration Terms
This event is hosted by Scientist.com. By registering and participating, you acknowledge that your personal data will be processed by Scientist.com. You also agree to receive email communication from Scientist.com about this webinar and other programs of similar nature. The sponsor of this webinar is Pelago Bioscience; by registering and participating, you acknowledge that your data will be processed in accordance with Pelago Bioscience’s Privacy Policy. You will receive email communication from Pelago Bioscience about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Scientist.com Privacy Policy
✓ Yes, I consent to the registration terms.*
Pelago Bioscience Privacy Policy
✓ Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.
Powered by BigMarker